ELAN Stock Recent News

Company expects approval and product supply in market before the end of third quarter GREENFIELD, Ind. , June 12, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) announced today that Zenrelia™ (ilunocitinib) has been granted a positive opinion by the European Medicines Agency's Committee for Veterinary Medicinal Products (CVMP), paving the way for the product's marketing authorization in the European Union in the next 60 days.

Elanco Animal Health (ELAN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Elanco Animal Health Incorporated (ELAN) and U.S. Physical Therapy (USPH). But which of these two companies is the best option for those looking for undervalued stocks?

Investors need to pay close attention to ELAN stock based on the movements in the options market lately.

The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief. Data reveals that nearly 9 in 10 dogs in the U.S. are "itchy dogs" according to their pet owners, having experienced symptoms of itchiness at some point in the year.1 Allergy season makes itch worse, with 83% of pet owners saying that increased pollen levels affect their dog's itch.1 Veterinarians are the most trusted ally in solving dogs' itch, and the majority of veterinarians say that itchiness is the most frustrating issue they deal with.1 Leading veterinarians and canine dermatologists, including Drs.

GREENFIELD, Ind. , May 28, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the appointment of Robert VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025.

GREENFIELD, Ind. , May 16, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that management will participate in upcoming investor conferences.

Elanco's shares have been pressured due to pipeline delays and debt from the Bayer acquisition, causing cautious optimism despite recent valuation resets. The company focuses on animal health, with balanced pet and livestock products, but struggles with debt and underwhelming growth since acquiring Bayer's animal health business. Despite some sales growth and debt reduction efforts, EBITDA and earnings are declining, limiting enthusiasm for significant investment.

Leerink analyst Daniel Clark raised the firm's price target on Elanco to $11 from $9.50 and keeps a Market Perform rating on the shares. The firm says the company's quarter was solid, and its exposure to tariffs was less than many feared. These two factors vs. bearish positioning are likely driving a bit of a squeeze in shares today. The updated guide appears prudent to Leerink, factoring in potential downside from pharmaceutical tariffs as well as the full impact of China tariffs at current rates, net of mitigation efforts. Ultimately, Elanco continues to be a second half of 2025 and 2026 growth story, the firm argues. 07 May

Elanco Animal Health Incorporated (NYSE:ELAN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Tiffany Kanaga - Head of Investor Relations Jeffrey Simmons - President and Chief Executive Officer Todd Young - Chief Financial Officer Conference Call Participants Jonathan Block - Stifel Michael Ryskin - Bank of America Andrea Alfonso - UBS Brandon Vazquez - William Blair Ekaterina Knyazkova - JPMorgan Navann Ty - BNP Paribas Mike DiFiore - Evercore ISI Erin Wright - Morgan Stanley Operator Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health First Quarter 2025 Earnings Conference Call.